CIK 0001400118 · <br>Emerging growth company
Sagimet Biosciences Inc.
Sign in to watch- Ticker
- SGMT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205991472
- Phone
- (650) 561-8600
- Business address
- 950 TOWER LANE, STE 1500, FOSTER CITY, CA, 94404
- Former names
- 3-V Biosciences, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-21 | Martins Eduardo Bruno Chief Medical Officer | Sale | −8,277 | $9.13 | $76K | 106,936 |
| 2025-07-21 | Rozek Elizabeth General Counsel and CCO | Sale | −10,780 | $9.13 | $98K | 183,726 |
| 2025-06-09 | Walbert Timothy P Director | Grant or award · Stock Option (Right to Buy) | +32,250 | 32,250 | ||
| 2025-06-09 | SEIDENBERG BETH C Director | Grant or award · Stock Option (Right to Buy) | +32,250 | 32,250 | ||
| 2025-06-09 | Phillips Anne M. Director | Grant or award · Stock Option (Right to Buy) | +27,268 | 27,268 | ||
| 2025-06-09 | Kemble George Director | Grant or award · Stock Option (Right to Buy) | +32,250 | 32,250 | ||
| 2025-06-09 | Jarrett Jennifer Director | Grant or award · Stock Option (Right to Buy) | +27,268 | 27,268 | ||
| 2025-06-09 | Hoelscher Paul W. Director | Grant or award · Stock Option (Right to Buy) | +32,250 | 32,250 | ||
| 2025-06-09 | GRAMMER ELIZABETH A Director | Grant or award · Stock Option (Right to Buy) | +32,250 | 32,250 | ||
| 2025-06-06 | SEIDENBERG BETH C Director | Grant or award · Stock Option (Right to Buy) | +28,522 | 28,522 | ||
| 2025-02-06 | Martins Eduardo Bruno Chief Medical Officer | Grant or award | +34,000 | 115,213 | ||
| 2025-02-06 | Martins Eduardo Bruno Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +138,000 | 138,000 | ||
| 2025-02-06 | Happel David President & CEO | Grant or award | +116,000 | 755,200 | ||
| 2025-02-06 | Happel David President & CEO | Grant or award · Stock Option (Right to Buy) | +472,000 | 472,000 | ||
| 2025-02-06 | Rozek Elizabeth General Counsel and CCO | Grant or award | +34,000 | 194,506 | ||
| 2025-02-06 | Rozek Elizabeth General Counsel and CCO | Grant or award · Stock Option (Right to Buy) | +138,000 | 138,000 | ||
| 2025-02-06 | Chauche Thierry Chief Financial Officer | Grant or award | +17,000 | 17,000 | ||
| 2025-02-06 | Chauche Thierry Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +69,000 | 69,000 | ||
| 2024-08-01 | Jarrett Jennifer Director | Grant or award · Stock Option (Right to Buy) | +113,895 | 113,895 | ||
| 2024-08-01 | Phillips Anne M. Director | Grant or award · Stock Option (Right to Buy) | +113,895 | 113,895 |
Page 3 of 10 · 194 trades